Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.

Ask your doctor whether Cologuard is a good option for you instead of or before considering a colonoscopy. Learn more about cancer screening and Medicare. The information on this website may ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential colon cancer or polyps. It’s popular due to its noninvasive nature and ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

There's a new blood test to screen for colorectal cancer, but a new study found it's not as effective as a colonoscopy or ...

Enter Cologuard, the at-home colon cancer screening test for people aged 45 and older. Perhaps best known by audiences for its cheeky approach to advertising, the Exact Sciences brand recently ...

Multitarget stool DNA test (Cologuard) This combines testing for ... finding small amounts of blood in your poop are based on the fact that blood vessels on large polyps and cancers are easily ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...